A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

June 19, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

HER2-positive Breast Cancer

Interventions

DRUG

BL-M07D1

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG

Pertuzumab

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG

Docetaxel

Administration by intravenous infusion for a cycle of 3 weeks.

Trial Locations (1)

RECRUITING

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou

All Listed Sponsors

collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY